Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab Alone or With Zanubrutinib in Newly Diagnosed Follicular Lymphoma
NCT05389293Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2022
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of mosunetuzumab in follicular lymphoma (FL), sponsored by Memorial Sloan Kettering Cancer Center. Started May 2022; status: recruiting.
02
Drugs
mosunetuzumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT05389293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05389293.